Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CAPIVASERTIB vs CAPMATINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CAPIVASERTIB vs CAPMATINIB: Safety Overview

Metric CAPIVASERTIB CAPMATINIB
Total FAERS Reports 1,691 2,301
Deaths Reported 285 583
Death Rate 16.9% 25.3%
Hospitalizations 464 388
Average Patient Age 66.2 yrs 71.9 yrs
% Female Patients 94.6% 53.9%
FDA Approval Date Nov 16, 2023 May 6, 2020
Manufacturer AstraZeneca Pharmaceuticals LP Novartis Pharmaceuticals Corporation
Route ORAL ORAL
Marketing Status Prescription Prescription